Hemolytic Disease: ABO and Rh Incompatibility

Hemolytic disease of the fetus and newborn (HDFN) arises when maternal antibodies cross the placenta and destroy fetal or neonatal red cells whose surface antigens the mother lacks. ABO and Rh(D) incompatibility are the classic causes: the resulting hemolysis accelerates bilirubin production and can produce severe anemia before birth and rapid, marked hyperbilirubinemia afterward.

Definition

Hemolytic disease of the fetus and newborn is an alloimmune condition in which maternal IgG antibodies against fetal red-cell antigens (most importantly Rh(D), and in the ABO system anti-A or anti-B) cross the placenta and cause immune-mediated destruction of fetal and neonatal erythrocytes, leading to anemia and accelerated unconjugated hyperbilirubinemia.

Scope

This entry covers the immunologic basis of ABO and Rh hemolytic disease, the contrast between the typically milder ABO form and the historically severe Rh(D) form, the role of maternal sensitization, and the place of HDFN among the hemolytic causes of neonatal hyperbilirubinemia. It is a reference overview of mechanism and evidence, not a protocol for antenatal or neonatal management.

Core questions

• How does maternal-fetal blood-group incompatibility lead to red-cell destruction?
• Why is Rh(D) hemolytic disease typically more severe than ABO incompatibility?
• How does maternal sensitization arise, and how is anti-D prophylaxis related to it?
• How does hemolysis in HDFN accelerate the rise in neonatal bilirubin?

Key concepts

• Alloimmunization (maternal sensitization)
• Rh(D) incompatibility
• ABO incompatibility
• Transplacental IgG antibody transfer
• Direct antiglobulin (Coombs) test
• Fetal anemia and hydrops fetalis
• Anti-D immunoglobulin prophylaxis
• Accelerated hemolytic hyperbilirubinemia

Mechanisms

When a mother lacks a red-cell antigen carried by her fetus, exposure to fetal cells (for Rh(D), typically at delivery or other sensitizing events) can prompt maternal IgG antibody production. In a subsequent pregnancy these IgG antibodies cross the placenta, bind fetal red cells, and mark them for destruction, producing fetal anemia that in severe cases leads to high-output failure and hydrops. ABO incompatibility differs: naturally occurring anti-A and anti-B antibodies can affect a first pregnancy, but the disease is usually milder because the relevant antigens are weakly expressed on fetal cells and are also present on other tissues that absorb antibody. After birth, ongoing hemolysis sharply increases bilirubin production at a time when hepatic clearance is immature, so hyperbilirubinemia in HDFN can rise rapidly. Anti-D immunoglobulin given to Rh-negative mothers prevents sensitization and has greatly reduced severe Rh disease.

Clinical relevance

HDFN is an important hemolytic cause of early and severe neonatal hyperbilirubinemia and of fetal anemia, and its prevention through anti-D prophylaxis is one of the landmark achievements of perinatal medicine. This entry summarizes the immunology and evidence for reference; antenatal screening, fetal monitoring, and neonatal management decisions are clinical matters governed by guidelines and are not given here as instructions.

Epidemiology

Routine anti-D immunoprophylaxis has markedly reduced the incidence of severe Rh(D) hemolytic disease in settings where it is available, leaving ABO incompatibility and antibodies to other red-cell antigens as relatively more prominent contributors. The overall burden of severe HDFN remains higher where antenatal screening and prophylaxis are less accessible.

Evidence & guidelines

Reviews by de Haas and colleagues and by Moise summarize the immunohematology, screening, and antenatal management of HDFN, including the role of anti-D prophylaxis and fetal surveillance. American Academy of Pediatrics hyperbilirubinemia guidance treats hemolytic disease, including isoimmune hemolysis, as a neurotoxicity risk factor that influences neonatal bilirubin thresholds. Specific antenatal protocols and neonatal thresholds belong to those sources and are not reproduced here.

History

The recognition of Rh hemolytic disease and erythroblastosis fetalis in the 1930s and 1940s, followed by the development and introduction of anti-D immunoglobulin prophylaxis in the late 1960s, transformed a once-common cause of fetal and neonatal death and disability into a largely preventable condition. Advances in fetal anemia assessment and intrauterine transfusion further improved outcomes for affected pregnancies.

Debates

How should pregnancies with red-cell alloimmunization be monitored and managed?

Approaches to antenatal surveillance of fetal anemia and the timing of intervention have evolved with noninvasive techniques, and management of alloimmunized pregnancies remains an area of specialized, evolving practice rather than a single fixed protocol.

Key figures

• Kenneth J. Moise
• Masja de Haas
• Cyril Clarke
• Ronald Finn
• Vincent Freda

Seminal works

• dehaas-2015
• moise-2008
• dennery-2001

Frequently asked questions

Why is ABO incompatibility usually milder than Rh disease?

The A and B antigens are weakly expressed on fetal red cells and are also present on other tissues that soak up antibody, so ABO hemolysis tends to be less severe, whereas Rh(D) antibodies cause more intense, progressive red-cell destruction.

How does anti-D immunoglobulin prevent Rh hemolytic disease?

Anti-D given to an Rh-negative mother clears fetal Rh-positive cells before her immune system is sensitized to them, preventing the formation of the antibodies that would attack red cells in a future pregnancy.